Corcept Therapeutics has been granted a patent for a crystalline anhydrate form of a compound called (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione. The patent also covers methods of making and using this compound. GlobalData’s report on Corcept Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Corcept Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Corcept Therapeutics's grant share as of September 2023 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline anhydrate form of a specific compound
A recently granted patent (Publication Number: US11760731B2) discloses a crystalline anhydrate form of a compound called (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I). The patent includes several claims related to the crystalline form of this compound.
Claims 1, 4, 7, and 10 describe the crystalline anhydrate form of Compound I. Each claim specifies a different X-ray powder diffraction (XRPD) pattern for the crystalline form, indicating the unique structural characteristics of each form. The XRPD patterns are provided in the claims, and they consist of specific peaks at different angles.
Claims 2, 3, 5, 6, 8, 9, 11, 12, 14, and 15 further characterize the crystalline forms by specifying their XRPD patterns. These claims provide additional details about the peaks observed in the XRPD patterns, which can be used to identify and confirm the presence of a specific crystalline form of Compound I.
Claim 16 describes a pharmaceutical composition that includes one of the crystalline forms of Compound I, along with one or more pharmaceutically acceptable excipients. This claim suggests that the crystalline form of Compound I has potential pharmaceutical applications.
Claim 17 adds that the pharmaceutical composition of claim 16 may also include one or more additional therapeutic agents. This claim indicates that the pharmaceutical composition can be combined with other therapeutic agents to enhance its effectiveness or provide additional therapeutic benefits.
Overall, this granted patent provides valuable information about the crystalline anhydrate forms of Compound I and their potential use in pharmaceutical compositions. The patent's claims specify the unique XRPD patterns of each crystalline form, allowing for their identification and characterization. The inclusion of additional therapeutic agents in the pharmaceutical composition further expands the potential applications of these crystalline forms.
To know more about GlobalData’s detailed insights on Corcept Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
